🎯 Drug Targets

Browse 16 drug targets with druggability analysis, composite scores, and clinical context

16
Targets
0
High Druggability
0.45
Avg Score
15
Target Classes
Druggability Distribution
High: 0Medium: 8Low: 5Unknown: 0
Avg druggability score: 0.500
Clinical Pipeline
Approved: 0Phase III: 1Phase II: 3Phase I: 9Preclinical: 3
Total compounds: 0 · Approved: 0
Filtered by: class=protein — 16 results
CHRNA7 CHRNA7 Protein Phase 2
Protein Medium Druggability
Score
0.60
Drug.
0.50
Safety
0.50
Drugs
0
Hyps
1
Papers
15
Prioritized from 1 SciDEX hypotheses, including: Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain Anti-Inflammatory Communication
C4B C4B Protein Phase 1
Protein Medium Druggability
Score
0.55
Drug.
0.50
Safety
0.50
Drugs
0
Hyps
1
Papers
13
Prioritized from 1 SciDEX hypotheses, including: Age-Dependent Complement C4b Upregulation Drives Synaptic Vulnerability in Hippocampal CA1 Neurons
CSGA CSGA Protein Phase 1
Protein Medium Druggability
Score
0.52
Drug.
0.50
Safety
0.50
Drugs
0
Hyps
1
Papers
11
Prioritized from 1 SciDEX hypotheses, including: Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-Seeding
SPTLC1 SPTLC1 Protein Phase 1
Protein Medium Druggability
Score
0.49
Drug.
0.50
Safety
0.50
Drugs
0
Hyps
1
Papers
6
Prioritized from 1 SciDEX hypotheses, including: APOE-Mediated Synaptic Lipid Raft Stabilization
TFEB TFEB Protein Phase 2
Protein Medium Druggability
Score
0.48
Drug.
0.50
Safety
0.50
Drugs
0
Hyps
1
Papers
12
Prioritized from 1 SciDEX hypotheses, including: The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction
TDC TDC Protein Phase 1
Protein Medium Druggability
Score
0.47
Drug.
0.50
Safety
0.50
Drugs
0
Hyps
1
Papers
6
Prioritized from 1 SciDEX hypotheses, including: Restoring Neuroprotective Tryptophan Metabolism via Targeted Probiotic Engineering
RHOT1 RHOT1 Protein Phase 1
Protein Low Druggability
Score
0.46
Drug.
0.50
Safety
0.50
Drugs
0
Hyps
1
Papers
8
Prioritized from 1 SciDEX hypotheses, including: Miro1-Mediated Mitochondrial Trafficking Enhancement Therapy
OCT4 OCT4 Protein Phase 2
Protein Low Druggability
Score
0.45
Drug.
0.50
Safety
0.50
Drugs
0
Hyps
1
Papers
23
Prioritized from 1 SciDEX hypotheses, including: Partial Neuronal Reprogramming via Modified Yamanaka Cocktail
DNAJB6 DNAJB6 Protein Phase 1
Protein Low Druggability
Score
0.45
Drug.
0.50
Safety
0.50
Drugs
0
Hyps
1
Papers
8
Prioritized from 1 SciDEX hypotheses, including: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor
CELL-TYPE-SPECIFIC CELL-TYPE-SPECIFIC Protein
Protein other Druggability
Score
0.45
Drug.
0.50
Safety
0.50
Drugs
0
Hyps
1
Papers
12
AGER AGER Protein Phase 1
Protein Medium Druggability
Score
0.44
Drug.
0.50
Safety
0.50
Drugs
0
Hyps
1
Papers
7
Prioritized from 1 SciDEX hypotheses, including: Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuroinflammatory Cascade
PGC1A PGC1A Protein Phase 1
Protein Medium Druggability
Score
0.41
Drug.
0.50
Safety
0.50
Drugs
0
Hyps
1
Papers
7
Prioritized from 1 SciDEX hypotheses, including: Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Circuits
PHB2 PHB2 Protein Phase 3
Protein Low Druggability
Score
0.41
Drug.
0.50
Safety
0.50
Drugs
0
Hyps
1
Papers
9
Prioritized from 1 SciDEX hypotheses, including: Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption
SYNTHETIC SYNTHETIC Protein
Protein other Druggability
Score
0.37
Drug.
0.50
Safety
0.50
Drugs
0
Hyps
1
Papers
7
DISEASE-CAUSING DISEASE-CAUSING Protein
Protein other Druggability
Score
0.35
Drug.
0.50
Safety
0.50
Drugs
0
Hyps
1
Papers
7
NURR1 NURR1 Protein Phase 1
Protein Low Druggability
Score
0.35
Drug.
0.50
Safety
0.50
Drugs
0
Hyps
1
Papers
7
Prioritized from 1 SciDEX hypotheses, including: Programmable Neuronal Circuit Repair via Epigenetic CRISPR